It was as guests of The University of Leiden that The Eurenvelopes which are still fusion competent. Steps toward this goal were presented including: opean Working Group on Gene Transfer Therapy (EWGT) held its fourth annual meeting between Nov-
• use of alternative retroviral systems, such as spleen ember 14 and 17, 1996. Set against a background of some necrosis virus, in which modification of the envelope disquiet about the ability of gene therapy to deliver on with targeting domains (such as single chain its clinical promise, 1,2 this meeting provided the forum in antibodies) still allows infectivity (R Dornburg); which gene therapy in Europe could be seen, heard and
• use of (tumour cell-associated) protease cleavage sites to some extent, judged.
to allow cleavage of the targeting domain away from The meeting came hot on the heels of a Cold Spring the rest of the envelope, which then retains a fusion Harbor meeting on Gene Therapy in which the principal competence via the wild-type receptor (S Russell); vector was, undoubtedly, the adenovirus. With the open-
• inclusion of proline rich spacers between specific binding Keynote Lecture coming from Alex van der Eb, it ing determinants and the fusion competent domains. seemed like the trend might be repeated on this side of These spacers will allow targeted binding to occur folthe Atlantic. However, the vector of the moment of the lowed by unmasking of the intact fusion machinery of EWGT was clearly the retrovirus, which subsequently the (amphotropic) wild-type envelope (F-L Cosset). dominated, in one form or another, much of the discussion. The focus on retrovirus structure and function Similar challenges are presented when attempting to tarreflected the overwhelming theme of this year's meeting get specific novel tropisms into the adenoviral envelope which was the pursuit of targeting efficiency for in vivo proteins (knob and fibre system) as detailed by D Curiel. gene delivery and was, perhaps, presciented at the start Once again, the structural restraints imposed by protein of the meeting when Claudio Bordignon, the outgoing folding and multimer assembly require that any modifipresident, handed the reins of power into the retrovirolocations to the knob protein do not disrupt trimer formagist hands of Olivier Danos.
tion and viral particle morphogenesis, complicating the Extensive knowledge of the form and function of the use of simple terminal ligand additions for redirecting envelopes of several retroviruses has accumulated from adenoviral binding. Therefore, Curiel described an efforts designed to redirect their binding potential to tarelegant antibody conjugate system in which an antibody get cells of choice and away from the often widely is used to block the natural binding of the viral proteins expressed wild-type receptors (JM Heard). 3 Indeed, such and attached conjugates can be used to introduce new efforts have proved very effective in several cases in that tropisms. Whatever the system, it is clear that gene therathe binding properties of retroviral envelopes can be pists interested in achieving the 'Holy Grail of Targeted redirected by inclusion of specific ligand-binding moiDelivery' (D Curiel) must first become highly versed in eties into engineered envelopes. However, although protein structure/function relationships, endeavours envelope substitutions with new ligands have occasionwhich will become considerably easier once crystal strucally been successful, 4 most often the redirection of bindtures of the relevant viral proteins are known. ing rarely correlates with a novel infectability and if it
The quest to make retroviral vectors suitable for the does it may not be as was initially intended (S Russell).
clinic does not revolve solely around the need to target For example, MLV envelopes engineered to express the them at the level of the cell surface. For instance, the EGF ligand on an amphotropic envelope framework prototype C-type vectors which form the basis of the tarshow a restriction of tropism to cells which do not geting discussions will not infect quiescent cells. This express the EGF receptor (S Russell). The explanation of property, combined with their low stability especially in these results appears to be that the modified envelopes the human circulation, makes them poor candidates for bind well enough to the surrogate receptor but the modiuse as in vivo delivery vehicles. Advances on two related fications prevent post-binding fusion events which are fronts were presented to address such concerns. In the critical for infection. In addition, the new receptors often first, Didier Trono described the construction, properties chaperone the viral particle into an entry pathway (such and uses of vectors based on the lentiviral genome of HIV as the lysosome) which destroys the virus before it can which can infect nondividing cells due to the presence of productively infect the cell. These results have higha nuclear targeting signal allowing penetration of an lighted the separation of function in the retroviral envelintact nuclear membrane. 5 In the second, Yas Takeuchi ope between cell binding and cell fusion and the chalreiterated the strategies by which his laboratory has generated producer cells which yield retroviral stocks lenge for the future is to produce redirected engineered which are resistant to the neutralising effects of human genicity. This immunogenicity derives in part from the complement. 6 continued expression of late viral genes despite the Takeuchi's presentation also included an assessment of deletion of the E1 region. As a result, MHC class I-depenthe chances of transmitting murine endogenous retrodent presentation of viral immunogens leads to clearance viruses to human cells from C-type packaging cell lines.
of transduced cells. 10 Although this may not be a problem This possibility was also emphasised by the demonin cancer therapy (indeed, it may be a positive benefit), stration of a replication-competent virus formed by such immune reactivities will be unacceptable and counrecombination between packaging functions and terproductive where the aim of gene delivery is to restore endogenous elements in an NIH3T3-derived packaging cell function by supplying a missing, or corrective, gene line (Chong) . 7 Takeuchi demonstrated that the packaging over a course of several administrations. The way forcells used to produce complement resistant viruses failed ward, as detailed in both oral and poster presentations, to mobilise any of the human endogenous retroviral seems to be via construction of improved vectors and elements tested for, but he also raised the concern that complementing packaging lines, in which deletion of organ transplantation from pigs to humans also carries most 11 or selected parts of the adenoviral genome -prethe risk of mobilisation of endogenous pig sequences.
dominantly the E3 and E4 regions (C Torrent) -reduce One way out of such problems was presented by D Klatzexpression of viral genes and, therefore, allow long-term mann who detailed the plasmovirus system, a persistence of transduced genomes without rapid retroviral/nonviral gene delivery system which does immune clearance. away with the need for producer cells. 8 Here, direct in Various other presentations made it clear that immune vivo transfer of a retroviral vector, along with the packagreactivity to the vector itself is only one aspect of a much ing functions, in plasmid DNA form, allow the generwider problem. The first round of clinical trials in which ation of retroviral vectors in situ without the need for provectors encoding both therapeutic and/or marker genes duction of packaging lines. The advantages of such a have been delivered into patients have shown that intersystem are clear -simple and cheap gene delivery should actions between the immune system and the encoded be achieved with the advantages of retroviral efficiency.
genes can also greatly influence the efficiency of gene However, concerns about the ability to control the in vivo transfer and long-term expression. Michael Blaese generation of unwanted viral species by unpredictable described how AIDS patients become immune to T cells recombination events remain.
previously labelled with the retrovirally encoded neo Although the emphasis was principally on retrogene, leading to the rapid rejection of subsequent adminviruses, a variety of other vector systems were covered istrations of T cells. Such effects will greatly restrict the including adeno, adeno-associated, papova and herpes efficacy of protocols in which modified cells, such as viruses. Indeed, the very first keynote lecture was delivfibroblasts or T cells, are selected ex vivo for infection with ered by Alex van der Eb, in which he detailed how the vectors encoding therapeutic genes and in which adenoviridae have touched many different aspects of repeated dosing with these gene-modified cells may be research in the past 20 years. These viruses have helped required -such as T cell transduction for systemic delivto reveal the mechanisms underlying processes as diverse ery of the ADA enzyme (M Blaese). An obvious solution as splicing, immune escape (via MHC down-regulation) would be to take the marker genes out of the vectors (R and cellular transformation, all properties which have Dornberg), leaving only the therapeutic cDNAs. important implications for their use as gene delivery Although this would make the virology more tedious it vehicles. In addition, the details of adenoviral vectors, may allow higher efficiency and persistence of transgene and their associated packaging cells, were described expression in vivo. However, data from D Wells using along with up-to-date advances from the speaker's own plasmid DNA to deliver the minidystrophin cDNA to laboratory on the generation of high titre, helper-free muscle fibres suggests that immune responses to theraviral stocks using helper cell lines in conjunction with peutic genes can be just as problematic. Thus, delivery of matched, nonoverlapping E1-deleted vectors.
the minidystrophin cDNA to muscle fibres was The development of new adenoviral vectors is being accompanied by the development of cytotoxic T cell driven by the need to overcome a central problem of critiresponses which cleared the transfected fibres. Many cal importance to clinical gene therapy -that of how to muscular dystrophy patients (or other candidates for predict, and control, the interactions of the immune sysgene replacement therapy), may never have seen epitem with both the administered vector and the topes encoded within the therapeutic genes. Therefore, therapeutic/marker genes encoded therein. The imporsuch immune responses may be expected to develop in tance of this issue recurred often in the meeting as part human patients and might, perversely, actually lead to of individual presentations and was recognised by the increased muscle fibre destruction rather than the hopedorganisers as warranting a dedicated workshop on the for restoration of muscle function. Furthermore, Wells immunological consequences of gene delivery.
showed that even mice transgenic for ␤-galactosidase Ever since the near lethal inflammatory complications could develop immune responses to ␤-gal following in a patient given high levels of adenoviral stocks were intramuscular injections of plasmid DNA encoding the described, 9 it has been clear that the interaction of the gene. Thus, gene delivery might lead to the breaking of immune system with vectors administered systemically tolerance even to 'self' therapeutic proteins. However, as has profound implications for both patient safety and for is often the case, one gene therapist's loss might be anthe efficiency with which such vectors can transduce tarother's gain. Depressing as such data may be for correcget populations. In Leiden, several reports addressed the tive gene therapy, so breaking tolerance to self proteins need to produce adenoviral vectors which can be admin-(in the form of tumour antigens such as MAGE or istered repeatedly to patients to exploit their high titres whilst simultaneously overcoming their high immunotyrosinase) may be highly desirable in the immuno-therapy of malignant disease (E Rankin, V Russo, In summary, we can report from Leiden on a healthy State of the Union for Gene Therapy in Europe. By the W Schmidt).
These problems emphasised that the overriding and next meeting in Paris in 1997, we will expect to hear more of how basic science has been used to create more recurring theme of this meeting was that the need for development of targeted vector systems remains the outefficient, more specific and more effective vectors. The challenge facing all of us, however, is how to translate standing requirement in the field. The development of such systems will allow gene therapy to progress beyond high quality basic research into human patients, where even the best laid plans will inevitably throw up unexthe first phase of its young existence in which patients' cells are modified ex vivo before being returned in vivo.
pected results from which we must simultaneously learn and benefit. In this respect, several presentations detailed results of human gene therapy trials using 
